Intervacc is trading at β¬0.06, down 5.32%, with sector weakness the likeliest available context, though no direct catalyst has been established.
- No company-specific announcement dated October 8 or 9 was found; Intervaccβs latest listed release was September 15.
- Supplied sector context reports biotech ETF XBI down 2.04%, while other coverage put its October 8 decline at approximately 0.5%, leaving the sector signal inconsistent.